Off the Scales

The Inside Story of Ozempic and the Race to Cure Obesity

Published Nov. 18, 2025

ISBN:
978-1-250-38906-0
Copied ISBN!
No rating (0 reviews)

Shortlisted for the Financial Times and Standard Chartered Business Book of the Year Award 2026!

The inside story of the creation of Ozempic and its revolutionary impact on public health.

A “cure” for obesity has long been the holy grail for the pharmaceutical industry, one that seemed unattainable until recent breakthroughs in type 2 diabetes research led to the development of Ozempic, a weight loss medication that activates a hormone in the stomach called GLP-1, making people feel fuller for longer. The treatment is so effective that it is already disrupting many industries―from healthcare to fast food to fashion―and it has quickly made its creator, Denmark’s Novo Nordisk, the most valuable company in Europe. But the impact of GLP-1s goes far beyond billion-dollar profits; a true long-term cure for obesity could save 40 percent of American adults from dangerous, preventable illnesses. And as more potential benefits emerge, one …

1 edition